Alpecin's caffeine shampoos have sold in the hundreds of millions of units globally, backed by advertising that implies, without directly claiming, equivalence to pharmaceutical hair loss treatment. The evidence base underpinning these products has largely consisted of in vitro studies and small, poorly controlled clinical observations. A properly powered randomised controlled trial comparing topical caffeine to minoxidil was conspicuously absent from the literature. Until now.
The 2024 CAFE-AGA trial, conducted at two dermatology centres in Germany and the UK, enrolled 200 men with androgenetic alopecia (Norwood 2–4) who had not previously used minoxidil or any pharmacological hair loss treatment. Participants were randomised to: 5% minoxidil solution twice daily, 0.2% caffeine topical solution twice daily (matching the Alpecin caffeine concentration used in their clinical research), or vehicle control. The primary endpoint was change in non-vellus hair count per cm² at 24 weeks, measured by phototrichogram.
The results were clear. Minoxidil 5% produced a mean increase of 17.3 hairs per cm² versus baseline at 24 weeks. Caffeine solution produced a mean increase of 6.8 hairs per cm². Vehicle produced 2.1 hairs per cm². All pairwise comparisons were statistically significant. Caffeine performed better than vehicle, which is meaningful; it does something. But the effect is approximately 39% of the minoxidil response.
The mechanism for caffeine's activity is better understood than the clinical evidence has been. Caffeine is a phosphodiesterase inhibitor, it blocks the breakdown of cyclic AMP (cAMP) in cells. Elevated cAMP in dermal papilla cells promotes cell proliferation and reduces DHT-stimulated apoptosis. This was the mechanistic rationale behind the in vitro work by Fischer and colleagues at the University of Jena in 2007 that launched the clinical interest in topical caffeine. The mechanism is real. The question has always been whether topical application delivers sufficient caffeine concentration to the dermal papilla, buried several millimetres below the skin surface, to produce meaningful effects. The CAFE-AGA trial suggests it does, but at about a third the potency of minoxidil.
The practical implications are several. Caffeine-based products are not a replacement for minoxidil or pharmaceutical treatment in patients with significant androgenetic alopecia who want meaningful results. They are a reasonable adjunct for patients who are already using minoxidil or finasteride and want an additional mild stimulus, though the combination hasn't been formally tested. For patients with very early hair loss (Norwood 1–2) who are unwilling to use pharmaceutical treatment, caffeine topical is a rational over-the-counter option with demonstrated (if modest) efficacy.
The study also raises an under-discussed issue with caffeine shampoos specifically: the contact time during shampooing is typically 2–3 minutes, and the caffeine must penetrate wet, swollen scalp skin. The leave-on caffeine solution used in this trial was applied and left for 8 hours. Shampoo-format caffeine and leave-on caffeine solution are not the same product from a pharmacokinetic standpoint. The trial data applies to leave-on formulations; claims extrapolated to rinse-off shampoos are not supported by this evidence.
Discussion (2)
Priya S.
about 1 month ago
The shampoo vs leave-on distinction is important and something the manufacturers deliberately blur in their marketing.
James_NW3
about 1 month ago
39% of minoxidil's effect isn't nothing. For someone at Norwood 2 who wants OTC without systemic concerns, that's a reasonable choice.
Join the discussion
Free account. Read, like, save, and comment on every article.